The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

It offers a variety of products, including faux wood, cellular, mini, vertical, vinyl and wood blinds. Shades are also ... Design consultations are free, and your sales professional will show ...

In this day and age, it’s hard enough to be able to afford a house, period. So once you’ve purchased one, you probably don’t ...

Intra-Cellular expects Caplyta to rake in about $665-685m in sales this year. Image credit ... met its primary endpoint of time to relapse during the 26-week double-blind treatment phase, with Caplyta ...

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

Black Friday is not until 29 November, but deals are already live. Here are the best US picks that I've found already: from ...

Chairman and CEO of Intra-Cellular Therapies. Total revenues were $175.4 million for the third quarter of 2024, compared to $126.2 million for the same period in 2023. Net product sales of CAPLYTA ...

Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsJennifer Cook Williams - Investor ...

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition ...

Good afternoon and welcome to today's conference call for Omeros Corporation. (Operator Instructions) Please be advised that this call is being recorded at the company's request and a replay will be ...